Medical Crossfire®: How the Experts Approach Testing and Treatment When Utilizing PARP Inhibitors for mCRPC

Release Date: October 07, 2021
Expiration Date: October 07, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in metastatic castration-resistant prostate cancer (mCRPC). In this educational program, these experts engage in spirited discussions on the practical implications of utilizing PARP inhibitors for their patients with mCRPC and the application of new data in clinical situations urologists are likely to encounter in real-world scenarios.
 
This educational activity is an archive of the live virtual Medical Crossfire^® symposium held on September 10, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.
 

Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of prostate cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with prostate cancer are also invited to participate.

Learning Objectives

• Describe the mechanistic rationale as well as testing recommendations for utilizing PARP inhibition in the clinic in patients with prostate cancer
• Determine strategies to effectively integrate PARP inhibitors into the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)
• Explain efficacy and safety data of currently approved PARP inhibitors for treatment of patients with mCRPC
• Assess emerging evidence and ongoing trials that are evaluating PARP inhibitors as part of combination strategies in mCRPC management settings

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Neal Shore, MD, FACS
Director, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, SC

Disclosures: Consultant: Abbvie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon, Exact Imaging, Exact Sciences, FerGene, Foundation Medicine, GenesisCare, lnvitae, Janssen, MDxHealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Propella, PreView, Sanofi Genzyme, Speciality Networks, Sesen Bio, Tolmar, UroGen; Speakers Bureau: Astellas, AstraZeneca, Bayer, Clovis Oncology, Foundation Medicine, Janssen, Merck, Pfizer, Guardant Health

Robert Dreicer, MD, MS, MACP, FASCO
Professor of Medicine and Urology
University of Virginia School of Medicine
Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Co-director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA

Disclosures: Grant research support: Arvinas, BMS, Seagen; Consultant: Astellas, AstraZeneca, Bayer, Eisai, Exelixis, EMD Serono, Gilead, Hinova, Infinity, Janssen, Merck, Myovant, Pfizer, Propella, Tavanta, Veru

Celestia S. Higano, MD, FACP
Adjunct Professor, Department of Urologic Sciences
University of British Columbia
Director, Prostate Cancer Supportive Care Program
Vancouver Prostate Centre
Vancouver, British Columbia, Canada

Disclosures: Grant research support: Clovis, Pfizer; Consultant: AstraZeneca, Clovis Oncology, Merck, Pfizer; Other: AstraZeneca IDMCs

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant research support: Ada Cap (Advanced Accelerator Applications), Agensys Inc, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly, Endocyte, Genentech, Gilead Sciences, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche; Consultant: Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead Sciences, Incyte, Ipsen, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seagen, UroGen; Shareholder: Bellicum(sold 7/2020), Tyme (sold 10/2019)

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.